Investigation Report on China's Levofloxacin Market, 2018-2022

SKU ID : CRI- 12855101

Publishing Date : 13-Dec-2018

No. of pages : 30


  • Desreportption
    The antibacterial drug segment is the largest and most profitable segment of the global pharmaceuticals market. As antibacterial drugs that develop rapidly in recent years, quinolones are receiving more and more attention from all over the world. As a laevo isomer of Ofloxacin, Levofloxacin has the same antibacterial spectrum, double antibacterial effect, and lower toxicity. Currently, fluoroquinolones are second only to cephalosporins and penicillins on the antibacterial market. Levofloxacin, a third-generation fluoroquinolone, was developed by Daiichi Pharmaceutical Co., Ltd. (merged with Sankyo Co., Ltd. into "Daiichi Sankyo" in 2005) and first marketed in Japan in 1994. In 1995, Levofloxacin APIs and tablets manufactured by Daiichi Pharmaceutical Co., Ltd. were admitted to the Chinese market. After that, Daiichi Pharmaceutical Co., Ltd. established its Chinese subsidiary Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. with an investment of USD 50 million. The subsidiary produces Levofloxacin preparations in China with the APIs from its parent company. The Levofloxacin tablets produced in China were launched in 1996 under the trade name Cravit. At that time, the retail price was about 7 CNY/tablet. Effective and inexpensive, Cravit saw its sales value rising on the Chinese market. Later, some Chinese companies developed generic Levofloxacin, and extended the dosage forms from tablets to injections, capsules, gels, etc.
    According to report’s market research, in 1998 when it had been launched in China for over one year, Levofloxacin became one of the top 100 drugs by sales value, and then showed an upward trend. The sales value of Levofloxacin declined from 2016 to 2017 after it reached CNY 1.23 billion in 2015. In 2017, China’s Levofloxacin market was dominated by Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory. By sales value, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. captured a market share of 29.1%. The injections, tablets, and eye drops accounted for about 63%, 20% and 13.7% respectively of China’s Levofloxacin market. The other dosage forms had a small market share.
    As environmental pollution and population aging intensify in China, there will be higher incidences of the main indications for Levofloxacin, for example, respiratory infection, urinary infection and intestinal infection. It is expected that China's Levofloxacin market will still have some growth potential from 2018 to 2022.
    Topics Covered:
    - Development environment of Levofloxacin in China
    - Market size of Levofloxacin in China
    - Competitive landscape of China's Levofloxacin market
    - Prices of Levofloxacin in China
    - Prospect of China's Levofloxacin market from 2018 to 2022

    Frequently Asked Questions

    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports